NO992005L - Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer - Google Patents

Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer

Info

Publication number
NO992005L
NO992005L NO992005A NO992005A NO992005L NO 992005 L NO992005 L NO 992005L NO 992005 A NO992005 A NO 992005A NO 992005 A NO992005 A NO 992005A NO 992005 L NO992005 L NO 992005L
Authority
NO
Norway
Prior art keywords
syndromes
estrogen
prevention
treatment
related diseases
Prior art date
Application number
NO992005A
Other languages
English (en)
Other versions
NO992005D0 (no
Inventor
Poul Jacobsen
Svend Treppendahl
Paul Stanley Bury
Anders Kanstrup
Lise Brown Christiansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO992005D0 publication Critical patent/NO992005D0/no
Publication of NO992005L publication Critical patent/NO992005L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Foreliggende oppfinnelse ved- rører terapeutisk aktive forbindelser med formel (I) (D en fremgangsmåte for fremstilling av disse forbindelsene, og farmasøytiske preparater som omfatter forbindelsene. De nye forbindelsene kan anvendes ved forhindring eller behandling av østro- genrelaterte sykdommer eller syndromer.
NO992005A 1996-10-28 1999-04-27 Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer NO992005L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK119996 1996-10-28
PCT/DK1997/000485 WO1998018778A1 (en) 1996-10-28 1997-10-28 Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Publications (2)

Publication Number Publication Date
NO992005D0 NO992005D0 (no) 1999-04-27
NO992005L true NO992005L (no) 1999-06-25

Family

ID=8102089

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992005A NO992005L (no) 1996-10-28 1999-04-27 Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer

Country Status (8)

Country Link
EP (1) EP0934299A1 (no)
JP (1) JP2001502710A (no)
AU (1) AU4772297A (no)
CA (1) CA2270056A1 (no)
IL (1) IL129618A0 (no)
NO (1) NO992005L (no)
WO (1) WO1998018778A1 (no)
ZA (1) ZA979649B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225782T1 (de) * 1996-12-13 2002-10-15 Chugai Pharmaceutical Co Ltd Benzopyranderivate
JP2000119187A (ja) * 1998-10-15 2000-04-25 Taisho Pharmaceut Co Ltd 抑うつ気分の予防または改善用組成物
CN101056868B (zh) 2004-09-21 2012-05-02 马休爱德华兹股份有限公司 取代的苯并二氢吡喃衍生物、药物及其在治疗中的应用
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
WO2012061409A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
PT3253208T (pt) 2015-02-02 2021-06-17 The Spanish National Cancer Res Centre Terapêuticas de combinação para utilização no tratamento do cancro da mama
CN115003295B (zh) * 2019-12-12 2025-05-06 冰洲石生物科技公司 具有雌激素受体降解活性的新型色满衍生物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders

Also Published As

Publication number Publication date
WO1998018778A1 (en) 1998-05-07
ZA979649B (en) 1998-04-28
IL129618A0 (en) 2000-02-29
CA2270056A1 (en) 1998-05-07
EP0934299A1 (en) 1999-08-11
JP2001502710A (ja) 2001-02-27
AU4772297A (en) 1998-05-22
NO992005D0 (no) 1999-04-27

Similar Documents

Publication Publication Date Title
AU563748B2 (en) Quinolone carboxylic acids
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
HK129093A (en) N-tert-butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl)isoquinoline-3-carboxamide & asparaginyl derivatives thereof
NO932620L (no) Amindiol-proteaseinhibitorer
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
ATE233250T1 (de) Saccharinderivate als proteolytische enzyminhibitoren
NO971625L (no) Nye peptider med immunomodulatoriske effekter
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
NO992003L (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
NO992010L (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
NO992008L (no) Nye (+)-enantiomerer av cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
NO992006L (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
NO992009L (no) Nye trans-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
NO992002L (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
NO992007L (no) Nye (-)-enantiomerer av cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
NO992004L (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
NO992005D0 (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
RU94046453A (ru) Производные изосерина, способ их получения, фармкомпозиция и способ лечения
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
RU93030824A (ru) Лекарственное средство для лечения псориаза "дермапихтол"
WO1998057910A3 (en) Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application